-+ 0.00%
-+ 0.00%
-+ 0.00%

RBC Capital Reiterates Outperform on ADC Therapeutics, Maintains $6 Price Target

Benzinga·05/05/2026 14:30:03
Listen to the news
RBC Capital analyst Leonid Timashev reiterates ADC Therapeutics (NYSE:ADCT) with a Outperform and maintains $6 price target.